Yes - it was being developed within the context of the FDA guidances that were under development. I'm sure there was a lot of back and forth concerning the proper selection of the trial population.
Apparently it ended up taking longer than both Gottleib and Missling expected.
"So in October 2017,we he reconfirmed three trials would start in 2017, this was all unknown??"
I think they may have known as early as August that trials would be not begin in 2017. Read the PR from Aug 7: http://anavex.com/anavex-reports-fiscal-third-quarter-2017-financial-results/. This was the first time no mention of 2017. Could have been an oversight but seems unlikely. True that 2017 was mentioned a couple of times after that. Not sure what to make of all of this but it doesn't smell right.
News 
Market Data 
Discover 
